Evidence map›Paper›PMID 36535741›Full record

ArticleBMJ case reports2022

ACTH-secreting metastatic prostate cancer with neuroendocrine differentiation.

Bashar Hassan, Yara Yazbeck, Vanessa Akiki, Ibrahim Salti, Arafat Tfayli

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bashar HassanFaculty of Medicine, American University of Beirut, Beirut, Lebanon.ORCID http://orcid.org/0000-0002-4037-8740
Yara YazbeckDivision of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Vanessa AkikiDivision of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Ibrahim SaltiDivision of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Arafat TfayliDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon at35@aub.edu.lb.
American University of Beirut Medical Center · LBAmerican University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cushing's syndrome (CS) due to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) can result from a variety of tumours and rarely from those of prostatic origin. We present a male patient in his early 60s with ACTH-secreting metastatic prostate adenocarcinoma with neuroendocrine differentiation (ICD-O code 8574/3) years after prostatectomy and androgen-deprivation therapy, initially presenting with Cushingoid features. After open radical prostatectomy and bilateral orchiectomy for disease recurrence, the patient was found to have metastatic liver and bone lesions highly suggestive of metastatic prostatic cancer. About 10% of cells on liver biopsy expressed ACTH, a finding consistent with EAS as the cause of CS. His stay was complicated with multiple infections and ultimate death. Hence, we report a case of metastatic prostate adenocarcinoma with neuroendocrine differentiation who presented with CS. We also emphasize the importance of adequate and timely treatment.

Indexed as

ACTH Syndrome, EctopicAdenocarcinomaCushing SyndromeProstatic NeoplasmsAdrenocorticotropic HormoneAndrogen AntagonistsCell DifferentiationHumansMaleNeoplasm Recurrence, LocalAdrenocorticotropic HormoneAndrogen AntagonistsAdrenal disordersEndocrine cancerMetabolic disordersProstate Cancer

Identifiers

PMID36535741
PMCPMC9764653
OpenAlexW4312050620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.